In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Imbalanced Innovation: The High Cost of Europe's "Free Ride"

Executive Summary

By keeping pharmaceutical prices and utilization artificially low, Europe is losing more economically than it gains. Lower drug prices and utilization for Europeans entail other costs , which are difficult to quantify but real, in terms of local industry competitiveness and health outcomes. Indeed, pharmaceutical industry investment and associated innovation has followed the money as the profit pool has shifted to the US, which now represents 62% of the industry's global returns compared with 18% for Europe. If current trends hold, Americans will spend four times as much on drugs per capita as Europeans by 2012. This will drive US R&D investments to double the size of those in Europe, compared with parity today, and will increase the focus on the US for initial drug launches. Pharmaceutical companies need to collaborate on solutions, as they have done in the US, focusing on working with a range of constituents to push governments to improve R&D and other investment incentives in Europe.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts